Enzon Pharmaceuticals Inc. (ENZN) 2009年年度报告「NASDAQ」.pdf

1、2009 ANNUAL REPORTGreater Focus.With the recent sale of its specialty pharmaceutical business,Enzon is now exclusively focused on advancing its novel pipeline for the benefit of patients with cancer.About Enzon PhArmAcEuticAlsEnzon Pharmaceuticals,inc.is a biopharmaceutical company dedicated to the

2、discovery and development of innovative medicines for patients with cancer.Enzons drug development programs utilize several cutting-edge approaches,including its industry-leading proprietary PEGylation platform,customized linker technology platform and mrnA antagonists using the locked nucleic Acid(

3、lnA)technology.Enzon receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology.2009 Annual report 1We have built an innovative and novel pipeline,improved the balance sheet and delivered operating efficiencies.DEAr shArEhol

4、DErs:2009 was a transforming year for Enzon.throughout 2009,we were focused on improving the overall structure of the company and advancing its novel pipeline.significant improvements were made in the specialty pharmaceutical business and the marketed products continued to demonstrate solid financia

5、l performance.several potential buyers continued to show interest in the specialty pharmaceutical business throughout 2009.in early 2010,we completed the sale of the specialty business to a global pharmaceutical company.this transaction has now transformed Enzon into a company exclusively focused on

6、 developing innovative compounds for patients with cancer.our current pipeline utilizes several cutting-edge technologies,including our proprietary PEGylation platform,customized linker technology platform and mrnA antagonists using the lnA technology.our most advanced compound in development,PEG-sn